摘要
目的研究黄芪注射液对白血病患者化疗后免疫功能的影响,并对影响因素进行评价和分析。方法将我院2016年1月至2019年1月收治的100例白血病患者以随机信封法平均分成黄芪组和对照组,对照组实施常规VDP方案化疗,黄芪组在对照组基础上增用黄芪注射液治疗。比较两组患者临床疗效、化疗前后免疫功能变化情况、生存质量评分以及不良反应发生情况,并采用Logistic回归分析影响白血病患者化疗后感染的相关因素。结果黄芪组患者临床治疗总有效率及生存质量均明显高于对照组(P<0.05)。化疗后黄芪组患者CD3+、CD4+水平及CD4+/CD8+均明显高于对照组(P<0.05)。黄芪组患者恶心呕吐、多汗、出血以及感染的发生率均明显低于对照组(P<0.05)。进一步Logistic回归分析显示,年龄、免疫功能低下以及未使用黄芪注射液均是白血病患者化疗后感染的独立危险因素(P<0.05)。结论黄芪注射液可有效提高白血病患者化疗效果,同时有效减轻化疗对患者免疫功能的影响,降低化疗相关不良反应发生风险。此外,年龄的增加、免疫功能的下降以及未使用黄芪注射液均会增加患者化疗后感染发生的几率,值得临床重点关注。
Objective To study the effect of astragalus injection on the immune function of leukemia patients after che-motherapy,and to analyze and evaluate the related factors.Methods A total of 100 patients with leukemia admitted to our hospital between January 2016 and January 2019 were included in this study,and were divided into astragalus group and control group by random envelope method.Patients in the control group received conventional VDP chemotherapy,while those in the astragalus group received astragalus injection plus conventional VDP chemotherapy.The clinical efficacy,changes of immune function before and after chemotherapy,quality of life score and incidence of adverse reactions were compared between the two groups.In addition,Logistic regression was used to analyze the factors affecting the post-chemo-therapy infection of leukemia patients.Results The clinical effective rate of astragalus group was higher than that of con-trol group(P<0.05).After chemotherapy,CD3+,CD4+levels and the CD4+/CD8+in the astragalus group were all higher than those in the control group(all P<0.05).The incidence of nausea,vomiting,hyperhidrosis,bleeding and infection in the as-tragalus group was lower than that in the control group(all P<0.05).Logistic regression analysis results showed that age,poor immune function and non-use of astragalus injection were independent risk factors for infection after chemotherapy in leukemia patients(all P<0.05).Conclusion Astragalus injection can effectively improve the effect of chemotherapy in pa-tients with leukemia,alleviate the impact of chemotherapy on patients′immune function,and reduce the risk of chemothera-py-related adverse reactions.In addition,with the increase of age,the decline of immune function and the non-use of as-tragalus injection would increase the incidence of infection after chemotherapy,which is worthy of clinical attention.
作者
张倩倩
封亚丽
张偲
宋俊贞
董雯
李晓红
李静
ZHANG Qianqian;FENG Yali;ZHANG Cai;SONG Junzhen;DONG Wen;LI Xiaohong;LI Jing(Department of Hematology,Hebei Provincial Hospital of Tradi-tional Chinese Medicine,Shijiazhuang,050051,Hebei,China;Department of Cardiovascular,Hebei Provincial Hospital of Tradi-tional Chinese Medicine,Shijiazhuang,050051,Hebei,China;Inpatient Department,Hebei Provincial Hospital of Tradi-tional Chinese Medicine,Shijiazhuang,050051,Hebei,China;Hebei Province Blood Center,Shijiazhuang,050051,Hebei,China;Department of Hematology,the First Hospital of Hebei Medical University,Shijiazhuang,050031,Hebei,China)
出处
《肿瘤药学》
CAS
2023年第5期610-614,共5页
Anti-Tumor Pharmacy
基金
北京市医学奖励基金会课题项目(YJHYXKYJJ-261)
河北省中医药管理局科研计划项目(2018009)。
关键词
白血病
黄芪注射液
免疫功能
化疗
不良反应
Leukemia
Astragalus injection
Immune function
Chemotherapy
Adverse reactions
